ArticleClinical ophthalmology (Auckland, N.Z.)2026
First Clinical Results of a Multicentric Prospective Study on the Visual Performance of Patients Implanted with a New Trifocal Aspheric Hydrophobic Intraocular Lens.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the postoperative visual performance of patients after bilateral implantation of a new trifocal aspheric hydrophobic intraocular lens (IOL) following cataract or refractive lens exchange surgery. Methods: This was a prospective, multicentric, open-label clinical study. Patients were implanted bilaterally with the AT ELANA 841P IOL targeted for emmetropia. One and 3 months postoperatively, subjective refraction, binocular uncorrected and distance-corrected visual acuities for far (UDVA, CDVA), intermediate (UIVA, DCIVA), and near (UNVA, DCNVA) distances, monocular and binocular defocus curves, binocular photopic and mesopic contrast sensitivity, patient satisfaction in terms of visual disturbance, and spectacle independence were recorded. Results: A total of 58 patients were evaluated. Three months postoperatively, the average postoperative spherical equivalent was 0.20±0.39D and 83.3% and 95.8% of eyes were within ±0.50D and ±1.00D, respectively. 88.5% of eyes showed refractive cylinder values of ≤0.50D, and 97.9% had values of ≤1.00D. For distance vision, 98% of patients had CDVA of 0 logMAR or better; for intermediate vision, 90% and 92% of patients had DCIVA of 0.10 logMAR or better at 80 and 66 cm, respectively; and for near vision 65% and 77% of patients presented DCNVA of 0.10 logMAR or better at 40 cm and preferred distance, respectively. The depth-of-focus from 0D was about 3.0D. The contrast sensitivity curves showed standard patterns under photopic and mesopic conditions. Questionnaires revealed that 87.2% of patients were either completely, very, or somewhat satisfied with their vision. A high spectacle independence rate of 85.1% was reported, while for visual symptoms, high percentages (59.6% to 100%) reported having them never or sometimes. Conclusion: The AT ELANA 841P trifocal aspheric hydrophobic IOL provides excellent accurate refractive outcomes with very good visual performance across multiple distances, resulting in high spectacle independence rate and satisfaction levels with minimal visual symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.